Autolus Therapeutics (AUTL) Competitors $1.45 +0.01 (+0.69%) Closing price 04:00 PM EasternExtended Trading$1.47 +0.02 (+1.38%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL vs. DYN, APGE, TWST, BEAM, CDTX, IMCR, BHVN, WVE, AUPH, and TVTXShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Twist Bioscience (TWST), Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), Immunocore (IMCR), Biohaven (BHVN), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Its Competitors Dyne Therapeutics Apogee Therapeutics Twist Bioscience Beam Therapeutics Cidara Therapeutics Immunocore Biohaven WAVE Life Sciences Aurinia Pharmaceuticals Travere Therapeutics Autolus Therapeutics (NASDAQ:AUTL) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Which has more risk & volatility, AUTL or DYN? Autolus Therapeutics has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Is AUTL or DYN more profitable? Autolus Therapeutics' return on equity of -56.18% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -56.18% -29.61% Dyne Therapeutics N/A -64.12%-56.75% Do analysts rate AUTL or DYN? Autolus Therapeutics currently has a consensus price target of $9.12, indicating a potential upside of 528.97%. Dyne Therapeutics has a consensus price target of $34.07, indicating a potential upside of 157.30%. Given Autolus Therapeutics' higher probable upside, equities research analysts plainly believe Autolus Therapeutics is more favorable than Dyne Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 3.06 Do insiders & institutionals have more ownership in AUTL or DYN? 72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by insiders. Comparatively, 14.1% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer AUTL or DYN? In the previous week, Dyne Therapeutics had 13 more articles in the media than Autolus Therapeutics. MarketBeat recorded 14 mentions for Dyne Therapeutics and 1 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 1.65 beat Dyne Therapeutics' score of 1.44 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dyne Therapeutics 14 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, AUTL or DYN? Autolus Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$10.12M38.13-$220.66M-$0.84-1.73Dyne TherapeuticsN/AN/A-$317.42M-$3.86-3.43 SummaryAutolus Therapeutics beats Dyne Therapeutics on 10 of the 15 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$383.24M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-1.7320.8978.4326.42Price / Sales38.13458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book0.909.9310.916.06Net Income-$220.66M-$53.38M$3.29B$266.28M7 Day Performance-7.64%0.05%0.01%-0.76%1 Month Performance-39.08%7.08%7.06%3.83%1 Year Performance-64.63%11.92%50.09%24.39% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics3.365 of 5 stars$1.45+0.7%$9.12+529.0%-62.6%$383.24M$10.12M-1.73330Positive NewsDYNDyne Therapeutics3.8134 of 5 stars$13.00+3.3%$34.07+162.1%-57.8%$1.79BN/A-3.37100News CoveragePositive NewsAPGEApogee Therapeutics3.2099 of 5 stars$36.94-3.5%$99.00+168.0%-21.2%$1.76BN/A-8.9491News CoveragePositive NewsTWSTTwist Bioscience3.8865 of 5 stars$27.39-4.2%$49.40+80.4%-36.5%$1.73B$312.97M0.00990Positive NewsBEAMBeam Therapeutics2.5511 of 5 stars$16.44-1.2%$48.45+194.7%-23.1%$1.68B$60.27M-3.65510News CoveragePositive NewsCDTXCidara Therapeutics3.7275 of 5 stars$64.13-3.4%$64.14+0.0%+447.3%$1.68B$1.27M-5.7690News CoverageIMCRImmunocore1.5523 of 5 stars$32.59-1.0%$56.89+74.6%-2.2%$1.66B$310.20M0.00320News CoverageBHVNBiohaven3.8678 of 5 stars$14.96-4.2%$54.23+262.5%-57.5%$1.65BN/A-1.95239Trending NewsAnalyst ForecastWVEWAVE Life Sciences4.7347 of 5 stars$9.94-2.1%$20.27+103.9%+44.1%$1.62B$108.30M-11.04240Trending NewsAnalyst ForecastAUPHAurinia Pharmaceuticals2.9926 of 5 stars$12.14-1.1%$12.00-1.2%+79.6%$1.62B$235.13M28.23300News CoveragePositive NewsTVTXTravere Therapeutics2.1663 of 5 stars$17.23-3.9%$32.21+87.0%+104.3%$1.60B$233.18M-8.45460News CoverageAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Dyne Therapeutics Competitors Apogee Therapeutics Competitors Twist Bioscience Competitors Beam Therapeutics Competitors Cidara Therapeutics Competitors Immunocore Competitors Biohaven Competitors WAVE Life Sciences Competitors Aurinia Pharmaceuticals Competitors Travere Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUTL) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AUTL Stock Alerts